Therachon fetches $35 mln Series A
France-based Therachon, a developer of treatments for achondroplasia, has secured $35 million in Series A funding. OrbiMed led the round with participation from New Enterprise Associates, Inserm Transfer Initiative and Versant Ventures. In conjunction with the funding, Dr. Stephen Squinto, a venture partner at OrbiMed and Dr. Sara Nayeem, a principal at NEA, have been added to the board of directors.
30 September 2015•3 mins read
